June 17, 2026 a 03:44 pm
BMY: Fundamental Ratio Analysis - Bristol-Myers Squibb Company
The BMY stock, representing Bristol-Myers Squibb Company, offers a diversified exposure in the biopharmaceutical sector. With a strong foundation in research and development, the company continues to deliver significant therapeutic advancements. Investors may find its broad portfolio, especially in oncology and immunology, appealing in a volatile market environment.
Fundamental Rating
Based on a recent evaluation, BMY's fundamental ratings are moderately favorable, highlighting its potential for long-term growth.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
The historical scores reflect a consistent evaluation over time, with the most recent data showing stability in key metrics.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-06-16 | 3 | 5 | 5 | 5 | 1 | 2 | 1 |
| Recent Past | 3 | 5 | 5 | 5 | 1 | 2 | 1 |
Analyst Price Targets
Analyst price targets suggest a moderate upside with the consensus leaning towards stability.
| High | Low | Median | Consensus |
|---|---|---|---|
| $75 | $40 | $60 | $62.6 |
Analyst Sentiment
The current analyst sentiment indicates a holding pattern, suggesting cautious optimism amidst uncertainty.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 19 | |
| Hold | 20 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Bristol-Myers Squibb Company presents as a viable option for risk-tolerant investors interested in the health care sector. The company’s robust product lineup and strong R&D focus provide considerable growth opportunities. However, its high debt-to-equity ratio and variable P/E scores may pose challenges. Analyst sentiments suggest a broadly neutral view, indicating potential stability in dividend income rather than aggressive capital gains. As with any pharmaceutical entity, success is closely tied to drug development and regulatory approvals.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years